Trial Profile
The effect of preoperative gemcitabine and nab-Paclitaxel compared to historical controls on RO surgical rate in patients with resectable pancreas cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Capecitabine; Fluorouracil
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GAP
- 01 Jul 2020 Status changed to discontinued, as per results published in the Annals of Surgical Oncology
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from recruiting to completed, according to abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).